1 / 35

ASTHMA, GENOMICS & FAMILY HEALTH HISTORIES: A New Strategy for Disease Prevention, Education and Treatment

ASTHMA, GENOMICS & FAMILY HEALTH HISTORIES: A New Strategy for Disease Prevention, Education and Treatment. Paul G. Eberle, Ph.D( abd ), RRT Assoc. Professor of Respiratory Therapy Weber State University.

lotus
Download Presentation

ASTHMA, GENOMICS & FAMILY HEALTH HISTORIES: A New Strategy for Disease Prevention, Education and Treatment

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ASTHMA, GENOMICS & FAMILY HEALTH HISTORIES:A New Strategy for Disease Prevention, Education and Treatment Paul G. Eberle, Ph.D(abd), RRT Assoc. Professor of Respiratory Therapy Weber State University

  2. It has been predicted that genomics will “revolutionize” public health as we know it today. -Utah Dept. of Health/Asthma Taskforce

  3. Genes & Family • Newsweek, Feb. 6, 2006 What science can tell you about your history and your health.

  4. Asthma • A serious personal and public health issue with far reaching medical, economic, and psychosocial implications. It can be characterized by: 1) Airway inflammation 2) Bronchial hyperreactivity 3) Reversible airway obstruction 4) Chronic eosinophilic bronchitis

  5. Implications • Asthma results from a combination of environmental triggers and genetic predisposition. • Varying degrees of hypersensitivity between and among patients and the onset of symptoms complicates a consistent description for asthma.

  6. Asthma Incidence • Most common chronic disease in U.S. • Present in approx. 7.7% population (22,771,528). • 8.8% in children <18yrs. (26,024,731). • ½ stricken before 10 yrs. of age. (American Lung Assn. Nat’l Health Interview Survey-2003).

  7. 10.4 million hospital outpatient visits • 2 million emergency dept. visits • 465,000 hospitalizations • 4,500 deaths were attributed to asthma in 2000.

  8. Asthma in the U.S. • Cost for treatment of asthma in the U.S. estimated to be 12.7 billion in 1998. (Weiss & Sullivan, 2001).

  9. Asthma in Utah • Cost in Utah for all providers was $2,972,061 (almost 3 million dollars). • Approx. 39% of all dollars spent on emergency department visits were due to asthma.

  10. Cost of asthma for Utah emergency department visits, 2003.

  11. Utah emergency department visit rates for females and males in years 2001, 2002, 2003 per 10,000 patients.

  12. Percentage of patient’s w/asthma seen in Utah emergency departments 2001 -2003.

  13. Early-phase • IgE (antigen-antibody sensitivity) allergic reaction • Attached to mast cell which release mediators Histamine Eosinophilic chemotactic factor of anaphylaxis (ECF-A) Neutrophil chemotactic factor (NCF) Prostiglandins Platelet-activating factor 1) Vasodilatation 2) Edema /irritation 3) Mucus secretion 4) Bronchoconstriction

  14. Heightened Reactivity • Luekotrienes Slow reacting substance of anaphylaxis (SRS-A) 1) Vasodilatation 2) Edema /irritation 3) Mucus secretion 4) Bronchoconstriction

  15. Late-phase • Eosinophilic leukocytosis Negative airway effects 1) Thickening of the bronchial wall 2) Inflammation (use glucocorticosteroids) 3) Thickening of the basement membrane 4) De-nuding of respiratory epithelium

  16. Triggers • Intrinsic Often no family history and onset later in life 1) Infection 2) Emotion 3) Cold air 4) Exercise 5) Smog 6) Irritants (tobacco smoke is the #1 modifiable factor i.e., 380,000 childhood cases of asthma can be attributed to second-hand smoke).

  17. Triggers • Extrinsic Allergic asthma triggers 1) Wind pollinating plants. i.e., trees, grass, weeds (40 µ). 2) Dry mold / Alter aria burnsii (1-2µ ). i.e., late summer- lower airway. 3) Animal dander (1-2 µ). 4) House dust mites. Non-allergic asthma 1) Occupational exposures

  18. Goal of Control Therapy • To restore lung function and return to “normal” activity. • Effective tx. suggestive w/15-20% increase in Fev1 Mild <2/wk normal lung function tx. short acting bronchodilator (treat symptoms). Mod >2/wk normal lung function tx. inhaled corticosteroid w/bronchodilator. Mod/Persistent includeNoc awakening, signs of impaired lung function, i.e., Fev1 <60% tx. steroid + long acting beta agonist &/or luekotriene inhibitor. Severe hypersensitivity w/ Noc awakening, Fev1 <50% tx. mast cell stabilizer, inhaled corticosteroid/beta agonist & leukotriene inhibitor w/long acting theophylline.

  19. Mortality in General Population • 1.4/100,000 in 1982 • 2.0/100,000 in 1991 • Mortality by race: Black 39/1000 pt’s w/asthma in 1982 62/1000 pt’s w/asthma in 1993 White 35/1000 pt’s w/asthma in 1982 51/1000 pt’s w/asthma in 1993 • Asthma prevalence is elevated in low-income populations with substantially higher fatality rates, hospital admissions, and emergency department visits.

  20. Gene Expression & the Environment • It is generally understood that a complex relationship exists between gene expressions and environmental interactions (Kleeberger & Peden, 2005) in respiratory diseases.

  21. Goals of Genomics • Genetic linkages in studies that range from replicating one gene at a time to complex multi-variant studies conclude that over 25 asthma or allergy susceptible loci have been identified. (Ober, 2005).

  22. Goals of these studies: 1) Identify susceptible individuals. 2) Intervene before the onset of disease. 3) Design drugs that are genospecific.

  23. The genotype effects at these loci were modified by the environment such that the same genotype was associated with protection from or risk for a phenotype depending upon an early life exposure. (Ober, 2005).

  24. Interaction between gene variants and environmental exposures hold great promise for developing new strategies for diagnosing, managing, and perhaps preventing or curing asthma. -U of Washington: Center of Genomics and Public Health

  25. Q: So, what do we do with this genetic information? • A: Develop protocols to address and participate in education, prevention and treatment strategies that minimize risk!

  26. Family Health History • Knowing your family history can save your life! -Dr. Richard Carmona, U.S. Surgeon General

  27. 10 Questions to ask your family at Thanksgiving • What traits seem to run in your family? • Did any of my family have health problems? • Were there any miscarriages? • How old were my family members when problems arose? • How old were my family members when they died? • What were the reasons they died? • Where were my family members born? • Did any of my family members smoke? • What other lifestyle habits did they have? • What types of allergies, reactions to food or medications did they have?

  28. When or who should get a genetic consultation? • Health problems that occur at an earlier age. • A health problem in more than one close family member. • A health problem that does not usually affect a certain gender. • Certain combinations of health problems within a family. • Birth defects, growth, or development problems, pregnancy concerns, and other known genetic conditions in the family.

  29. What will I learn? • Asses your risk for a health problem based on your family health history. • Diagnose a health problem and cause for it. • Decide if genetic testing is an option. • Give you facts about treatment or management of a problem. • Refer you and your family members to support groups and resources.

  30. Where can I learn more? • Huntsman Cancer Institute, www.huntsmancancer.org. • Family Cancer Assessment Clinic, (801) 587-9555. • For other genetic questions, call (801) 585-0100 or toll-free at 866-275-0243. • Intermountain Healthcare, Clinical Genetics Institute Genetic specialist, call (801) 408-5014. • University of Utah Hospital Genetic counseling and patient care issues, call (801) 581-8943.

  31. References • Barr, R.G., Cooper, D.M., Speizer, F.E., Drazen, J.M., Camargo, C.A., Jr. (2001). Beta(2) adrenoceptor polymorphism and body mass index are associated with adult-onset asthma in sedentary but not active. Chest, 120, p. 1474-9. • Gern, J.E., Reardon, C.L., Hoffjan, S., Nicolae, D., Li, Z., Roberg, K.A., et al. (2004). Effects of dog ownership and genotype on immune development and atopy in infancy. Journal of Allergy and Clinical Immunology, 113, p. 307-14. • Gilliland, F.D., Li, Y.F., Saxon, A., Diaz-Sanchez, D. (2004). Effect of glutathione-S-transferase M1 and P1 genotypes on xenobiotic enhancement of allergic responses: Randomized, placebo-controlled crossover study. Lancet, 363, p. 119-25. • Hoffjan, S., Nicolae, D. Ostrovnaya, I., Roberg, K., Evans, M. Mirel, D,B., et al. (2005). Gene-environment interaction effects on the development of immune responses in the first year of life. American Journal of Human Genetics, 76, p. 696-704. • Kalb, C. (2006, Feb.). In our blood. Newsweek Magazine, p. 47 – 55. • Kleeberger, S.R. & Peden, D. (2005). Gene-environment interactions in asthma and other respiratory diseases. Annual Review of Medicine, 56, p. 383 – 400. • Marshall, R., Webb, S., Bellingham, G.J. et al. (2002). Angiotensin converting enzyme insertion/deletion polymorphism is associated with susceptibility and outcome in acute respiratory distress syndrome. American Journal of Respiratory Critical Care, 166, p. 646 – 50.

  32. McIntire, J.J., Emetsu, S.E., Macaubas, C., Hoyte, E.G., Cinnioglu, C., Cavalli-Sforza, L.L.. et al. ( 2003). Immunology: Hepatitis A virus link to atopic disease. Nature, 425, p. 576. • Nicolae, D., Cox, N.J., Lester, L.A., Schneider, D. Tan, Z., et al. (2005). Fine mapping and positional candidate studies identify HLA-G as an asthma susceptibility gene on chromosome 6p21. American Journal of Human Genetics, 76, p. 349-57. • National Heart, Lung & Blood Institute. National asthma education and prevention program. http://www.nhbli.nih.gov/about/naep_pd.htm. • Ober, C. (2005). Perspectives on the past decade of asthma genetics. Journal of Allergy and Clinical Immunology, 116,(2), p. 274 – 278. • Sanak, M., Pierzchaiska, M., Bazan,-Socha, S. & Szczeklik, A. (2000). Enhanced expression of the leukotriene C(4) synthase due to overactive transcription of an allele variant associated with aspirin-intolerant asthma. American Journal of Respiratory Cell and Molecular Biology, 23, p. 290-6. • Utah Asthma Program, Bureau of Health Promotion (2005). Asthma Emergency Department Report. Salt Lake City, UT: Utah Department of Health. • Utah Department of Health. Make family health history a tradition. http://www.health.utah.gov/genomics. • Wang, Z., Chen, C., Niu, T., Yang, J., Wang, B., et al. (2001). Association of asthma with beta(2) adrenergic receptor gene polymorphism and cigarette smoking. American Journal of Respiratory and Critical Care Medicine, 163, p. 1404-9. • Weiss, K.B. & Sullivan, S.D. (2001). The health economics of asthma and rhinitis: Assessing the economic impact. Journal of Allergy & Clinical Immunology, 107,(1), p. 3-8. • Werner, M., Topp, R., Wimmer, K., Richter, K. Bischof, W., Wjst, M., et al. (2003). TLR4 gene variants modify exotoxin effects on asthma. Journal of Allergy and Immunology, 112, p. 323-30.

  33. Thank You! • Utah Department of Health, Asthma Taskforce Libbey Chuy, MPH, Health Program Specialist Charrissa Wood, Program Specialist Jenny Johnson, CHES, Health Program Specialist

More Related